This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sibonga, J. D. Articles by Turner, R. T. Search for Related Content PubMed PubMed Citation Articles by Sibonga, J. D. Articles by Turner, R. T.

Dose-Response Effects of 2-Methoxyestradiol on Estrogen Target Tissues in the Ovariectomized Rat

Departments of Orthopedics (J.D.S., S.L., G.L.E., R.T.T.) and Biochemistry and Molecular Biology, (R.T.T.), Mayo Clinic, Rochester, Minnesota 55905; and EntreMed Inc. (V.S.P., S.J.G.), Rockville, Maryland 20850

Address all correspondence and requests for reprints to: Jean D. Sibonga, Ph.D., Division of Orthopedic Research, Mayo Clinic, 200 First Street SW, Medical Sciences Building 3-69, Rochester, Minnesota 55905. E-mail: sibonga.jean{at}mayo.edu.

In three experiments, we evaluated the pharmacological effects of 2-methoxyestradiol (2ME₂) on several estrogen target tissues. Experiment 1: we gavaged recently ovariectomized (OVX) 9.5-wk-old rats with 2ME₂ at doses of 0, 0.1, 1, 4, 20, and 75 mg/kg in a 21-d dose-response study. 2ME₂ reduced body weight and serum cholesterol, increased uterine weight and epithelial cell height, and inhibited longitudinal and radial bone growth compared with values in the untreated OVX rat. All doses of 2ME₂ maintained cancellous bone mass at the baseline level, the lowest effective dose being 20-fold less than a uterotrophic dose. Experiment 2: in an 8-wk experiment in adult OVX rats, a nonuterotrophic dose of 2ME₂ (4 mg/kg·d) suppressed body weight gain, inhibited bone formation in cancellous bone and partially prevented bone loss in the tibial metaphysis. Experiment 3: in weanling rats, ICI 182,780 did not antagonize the effect of 2ME₂. We conclude that 2ME₂ antagonizes the skeletal changes that follow OVX at doses that have minimal or no effects in the uterus in both young and adult rats; 2ME₂ does not appear to act via estrogen receptors and is active on bone at doses well below those required for tumor suppression in mice. 2ME₂, through a novel pathway, may be a useful alternative to conventional hormone replacement therapy for prevention of postmenopausal bone loss.

This article has been cited by other articles:

				R. Shao, M. Nutu, B. Weijdegard, E. Egecioglu, J. Fernandez-Rodriguez, E. Tallet, V. Goffin, C. Ling, and H. Billig Differences in Prolactin Receptor (PRLR) in Mouse and Human Fallopian Tubes: Evidence for Multiple Regulatory Mechanisms Controlling PRLR Isoform Expression in Mice Biol Reprod, October 1, 2008; 79(4): 748 - 757. [Abstract] [Full Text] [PDF]

				A. Parada-Bustamante, P. A Orihuela, M. Rios, P. A Navarrete-Gomez, C. A Cuevas, L. A Velasquez, M. J Villalon, and H. B Croxatto Catechol-O-Methyltransferase and Methoxyestradiols Participate in the Intraoviductal Nongenomic Pathway Through Which Estradiol Accelerates Egg Transport in Cycling Rats Biol Reprod, December 1, 2007; 77(6): 934 - 941. [Abstract] [Full Text] [PDF]

				M. Cicek, U. T. Iwaniec, M. J. Goblirsch, A. Vrabel, M. Ruan, D. R. Clohisy, R. R. Turner, and M. J. Oursler 2-Methoxyestradiol Suppresses Osteolytic Breast Cancer Tumor Progression In vivo Cancer Res., November 1, 2007; 67(21): 10106 - 10111. [Abstract] [Full Text] [PDF]

				R. K. Dubey, B. Imthurn, and E. K. Jackson 2-Methoxyestradiol: A Potential Treatment for Multiple Proliferative Disorders Endocrinology, September 1, 2007; 148(9): 4125 - 4127. [Full Text] [PDF]

				J. Bourghardt, G. Bergstrom, A. Krettek, S. Sjoberg, J. Boren, and A. Tivesten The Endogenous Estradiol Metabolite 2-Methoxyestradiol Reduces Atherosclerotic Lesion Formation in Female Apolipoprotein E-Deficient Mice Endocrinology, September 1, 2007; 148(9): 4128 - 4132. [Abstract] [Full Text] [PDF]

				T. E. Sutherland, M. Schuliga, T. Harris, B. L. Eckhardt, R. L. Anderson, L. Quan, and A. G. Stewart 2-Methoxyestradiol Is an Estrogen Receptor Agonist That Supports Tumor Growth in Murine Xenograft Models of Breast Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1722 - 1732. [Abstract] [Full Text] [PDF]

				L. M. Harrison-Bernard, I. H. Schulman, and L. Raij Postovariectomy Hypertension Is Linked to Increased Renal AT1 Receptor and Salt Sensitivity Hypertension, December 1, 2003; 42(6): 1157 - 1163. [Abstract] [Full Text] [PDF]